Literature DB >> 8207389

The nuclear location of PML, a cellular member of the C3HC4 zinc-binding domain protein family, is rearranged during herpes simplex virus infection by the C3HC4 viral protein ICP0.

G G Maul1, R D Everett.   

Abstract

ND10 are nuclear domains of unknown function that become abundant in response to stress. Infection by herpes simplex virus type 1 (HSV-1) causes the apparent disappearance of these domains, an effect that requires the expression of the immediate early protein ICP0. Previously, we have shown that there are a number of cellular antigens in the ND10. In this report, we show that one of these proteins is PML, a member of the C3HC4 zinc-binding domain family which also includes ICP0. The C3HC4 domain of ICP0 is essential for the apparent release of PML from the ND10, although the interaction of ICP0 with ND10 is determined by a small region near its carboxy terminus. PML and other ND10 proteins are not lost after removal from ND10 but deposited at the nuclear envelope or nuclear envelope modifications during later parts of the replication cycle. ICP0 is required for the onset of low multiplicity infections, and has been implicated in the process of reactivation from HSV latency. Therefore, the interaction between ICP0 and the ND10 domains, specifically PML, may be important for the outcome of virus-cell interactions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8207389     DOI: 10.1099/0022-1317-75-6-1223

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  180 in total

1.  Requirements for the nuclear-cytoplasmic translocation of infected-cell protein 0 of herpes simplex virus 1.

Authors:  P Lopez; C Van Sant; B Roizman
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0.

Authors:  W E Hobbs; N A DeLuca
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

3.  Efficient activation of viral genomes by levels of herpes simplex virus ICP0 insufficient to affect cellular gene expression or cell survival.

Authors:  W E Hobbs; D E Brough; I Kovesdi; N A DeLuca
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

4.  Nuclear localization and shuttling of herpes simplex virus tegument protein VP13/14.

Authors:  M Donnelly; G Elliott
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Specific destruction of kinetochore protein CENP-C and disruption of cell division by herpes simplex virus immediate-early protein Vmw110.

Authors:  R D Everett; W C Earnshaw; J Findlay; P Lomonte
Journal:  EMBO J       Date:  1999-03-15       Impact factor: 11.598

6.  Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption.

Authors:  S Müller; A Dejean
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

7.  Expression of herpes simplex virus ICP0 inhibits the induction of interferon-stimulated genes by viral infection.

Authors:  Kasey M Eidson; William E Hobbs; Brian J Manning; Paul Carlson; Neal A DeLuca
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

8.  Truncation of the C-terminal acidic transcriptional activation domain of herpes simplex virus VP16 renders expression of the immediate-early genes almost entirely dependent on ICP0.

Authors:  K L Mossman; J R Smiley
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

9.  Herpes simplex virus immediate-early protein ICP0 is targeted by SIAH-1 for proteasomal degradation.

Authors:  Claus-Henning Nagel; Nina Albrecht; Kristijana Milovic-Holm; Lakshmikanth Mariyanna; Britta Keyser; Bettina Abel; Britta Weseloh; Thomas G Hofmann; Martha M Eibl; Joachim Hauber
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

10.  ICP0 induces the accumulation of colocalizing conjugated ubiquitin.

Authors:  R D Everett
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.